Centessa Pharmaceuticals (CNTA) Share-based Compensation (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Share-based Compensation data on file, last reported at $10.6 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $10.6 million, up 34.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.6 million (up 1.11% YoY), and the FY2025 annual result was $31.0 million, down 7.7% from the prior year.
• Share-based Compensation improved to $10.6 million in Q1 2026 per CNTA's latest filing, from $7.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $10.6 million in Q1 2026 and troughed at $5.6 million in Q2 2022.
• A 5-year average of $7.6 million and a median of $7.6 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 109.37% in 2022, then declined 14.89% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $6.6 million in 2022, then rose by 12.29% to $7.4 million in 2023, then gained by 12.09% to $8.3 million in 2024, then declined by 4.71% to $7.9 million in 2025, then surged by 33.13% to $10.6 million in 2026.
• Business Quant data shows CNTA's Share-based Compensation at $10.6 million in Q1 2026, $7.9 million in Q4 2025, and $7.2 million in Q3 2025.